What may be underestimated
From the latest edition of each brief.
Biotech & Pharma Intelligence
Hitting normal RAS too. Daraxonrasib blocks unmutated RAS as well as mutant forms, per its label, and Erasca says ERAS-0015 is designed to do the same. That may widen the patients who respond, but it may also raise toxicity in longer first-line use; Erasca’s grade 5 pneumonitis is one case, and the combination data give no grade 3 or higher rates. Analysis
AI & Technology Intelligence
If Apple limits how much access third-party agents get on the Mac, the companies that own the operating system may set the terms for every agent built on top. Speculation

